Ridgewood Investments LLC Grows Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Ridgewood Investments LLC grew its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 40.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,735 shares of the biopharmaceutical company’s stock after purchasing an additional 8,913 shares during the period. Ridgewood Investments LLC’s holdings in Royalty Pharma were worth $784,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of RPRX. Blue Trust Inc. increased its stake in shares of Royalty Pharma by 362.7% during the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 943 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Royalty Pharma during the third quarter valued at $61,000. GAMMA Investing LLC increased its stake in shares of Royalty Pharma by 31.4% during the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 590 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Royalty Pharma by 32.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 655 shares during the period. Finally, Transamerica Financial Advisors Inc. increased its stake in shares of Royalty Pharma by 99.9% during the third quarter. Transamerica Financial Advisors Inc. now owns 3,459 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,729 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Citigroup dropped their price objective on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $41.67.

Royalty Pharma Stock Up 10.3 %

NASDAQ RPRX traded up $2.69 during trading on Friday, hitting $28.89. The company’s stock had a trading volume of 1,863,065 shares, compared to its average volume of 2,073,156. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The company has a market cap of $17.02 billion, a PE ratio of 14.97, a P/E/G ratio of 4.36 and a beta of 0.47. The business’s 50 day simple moving average is $25.90 and its 200-day simple moving average is $27.02. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $31.66.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.